Financings Of The Fortnight Checks The Rime Of The Ancient Mariner
This article was originally published in The Pink Sheet Daily
Executive Summary
Financing updates on Archimedes Pharma, NPS Pharmaceuticals, Optimer, and Ubiquigent.
You may also be interested in...
Financings Of The Fortnight: Hybrigenics, Neurocrine, Xoma, Zogenix, Seaside
Creative, non-dilutive financings highlighted the fundraising activity over the past two weeks.
Valuation Watch: Anti-Infectives a Rare Bright Spot for Last Crop of Biotech IPOs
Most of the 15 biotech IPOs in the US in 2007 have performed poorly on the public markets. There have been exceptions: Sirtris was acquired by GSK at a significant premium to its IPO price. And anti-infectives focused biotechs Pharmasset and Optimer have outclassed their peers as they have outperformed the market.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.